Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 60

Sort by

Sort Order Select

Journal Articles

Outcomes of Relapsed/Refractory Multiple Myeloma Patients Receiving Sequential Therapies after Exposure to T-Cell Redirected or BCMA-Targeted Novel Immunotherapies

Rintu Sharma, Pamella Paul, Esther Masih-Khan, Eshetu G. Atenafu, Harjot Vohra, Sita D. Bhella, Christine I Chen, Vishal Kukreti, Guido Lancman, Donna E Reece, A. Keith Stewart, Rodger E Tiedemann, Chloe Yang, Suzanne Trudel

Blood (2024) 144 (Supplement 1): 1956.

https://doi.org/10.1182/blood-2024-207919

Published: 2024

Journal Articles

Real-World Experience with CPX-351 for Secondary Acute Myeloid Leukemia: Comparison with FLAG-IDA in a Propensity Score Matching Analysis

Blood (2024) 144 (Supplement 1): 1506.

https://doi.org/10.1182/blood-2024-204004

Published: 2024

Journal Articles

Final Results of the Canadian Myeloma Research Group Trial of Cybord Induction, Double-Alkylator Conditioning with High-Dose Intravenous Busulfan + Melphalan, ASCT and Continuous Lenalidomide Maintenance for Patients with Newly Diagnosed Multiple Myeloma (CMRG-001)

Donna E Reece, Giovanni Piza Rodriguez, Mariela A Pantoja, Eshetu G Atenafu, Darrell White, Irwindeep Sandhu, Julie Stakiw, Michael Sebag, Terrance Comeau, Kevin Song, Jean Roy, Martha L Louzada, Arleigh McCurdy, Vishal Kukreti, Suzanne Trudel, Anca Prica, Rodger E Tiedemann, Christine I Chen

Blood (2024) 144 (Supplement 1): 3376.

https://doi.org/10.1182/blood-2024-206247

Published: 2024

Journal Articles

Real World Outcomes in Adult Histiocytosis: 23-Year Canadian Single Center Analysis

Rintu Sharma, Alfredo H. De La Torre, Umberto Falcone, Eshetu G. Atenafu, Harjot Vohra, Jan Delabie, Michael Crump, Vishal Kukreti

Blood (2024) 144 (Supplement 1): 5388.

https://doi.org/10.1182/blood-2024-209411

Published: 2024

Journal Articles

Long Term Survivors (>15 years) of Multiple Myeloma: Patient Characteristics and Morbidity Burden

Rintu Sharma, Karla Alexandra Sanchez, Badraa Muharib, Esther Masih-Khan, Eshetu G. Atenafu, Harjot Vohra, Sita D. Bhella, Christine I Chen, Guido Lancman, Vishal Kukreti, Anca Prica, Donna E Reece, Rodger E Tiedemann, Suzanne Trudel, Chloe Yang, A. Keith Stewart

Blood (2024) 144 (Supplement 1): 7841.

https://doi.org/10.1182/blood-2024-208502

Published: 2024

Journal Articles

Correlation Amongst Scoring of Various Frailty Tools in Myeloma Patients Undergoing Autologous Stem Cell Transplantation

Anup Joseph Devasia, Sahar Khan, Harminder K Paul, Frédéric Larose, Eshetu G. Atenafu, Donna E. Reece, Suzanne Trudel, A. Keith Stewart, Sita Bhella, Vishal Kukreti, Chloe Yang, Rodger E Tiedemann, Anca Prica, Monica Monchis, Eugene Leung, Susan Jomah, Zubaida Mohamed, Christine Chen

Blood (2022) 140 (Supplement 1): 10043–10044.

https://doi.org/10.1182/blood-2022-170681

Published: 2022

Journal Articles

Comparison of Clinical Outcomes between Transplant and Non-Transplant Therapies in Myelofibrosis Following Failure of First-Line JAK-Inhibitor

James T. England, Eshetu G. Atenafu, James A. Kennedy, Burhan Goraya, Verna Cheung, Taylor Nye, Karine Gauthier, Marta B. Davidson, Aniket Bankar, Hassan Sibai, Dawn Maze, Auro Viswabandya, Vikas Gupta

Blood (2022) 140 (Supplement 1): 9724–9725.

https://doi.org/10.1182/blood-2022-165272

Published: 2022

Journal Articles

Real-World Outcomes and Adverse Events of Elderly Patients with Ph-Negative Acute Lymphoblastic Leukemia Treated with a Pediatric-Inspired Protocol

Maria Agustina Perusini, Jad Sibai, Eshetu G. Atenafu, Aniket Bankar, Mark D. Minden, Vikas Gupta, Dawn Maze, Marta B. Davidson, Steven M. Chan, Aaron D. Schimmer, Guillaume Richard-Carpentier, Josephine Anne Lucero, Claire Andrews, Dennis Dong Hwan Kim, Karen Yee, Andre C. Schuh, Hassan Sibai

Blood (2022) 140 (Supplement 1): 6039–6041.

https://doi.org/10.1182/blood-2022-169406

Published: 2022

Journal Articles

Acute Lymphoblastic Leukemia in Patients 60 Years and Older Treated with Pediatric-Inspired Protocols, 20 Years of Follow-up

Maria Agustina Perusini, Eshetu G. Atenafu, Aniket Bankar, Vikas Gupta, Mark D. Minden, Jad Sibai, Dawn Maze, Marta B. Davidson, Steven M. Chan, Fernando Binder, Guillaume Richard-Carpentier, Salman Alharbi, Claire Andrews, Karen Yee, Andre C. Schuh, Hassan Sibai

Blood (2022) 140 (Supplement 1): 3176–3177.

https://doi.org/10.1182/blood-2022-170121

Published: 2022

Journal Articles

Do Adult Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Patients Require Allogeneic Transplant in First Remission (CR1)?

Fatima M Khadadah, Claire Andrews, Eshetu G. Atenafu, Andre C. Schuh, Dawn Maze, Karen Yee, Osamah Jamal S. Jarallah, Mark D. Minden, Aaron D. Schimmer, Steven M. Chan, Vikas Gupta, Dennis Dong Hwan Kim, Hassan Sibai

Blood (2022) 140 (Supplement 1): 3169–3171.

https://doi.org/10.1182/blood-2022-169342

Published: 2022

Journal Articles

Which Asparaginase Formulation Retained Higher VTE Incidence Risk in Post Treatment Adult Acute Lymphoblastic Leukemia? a Meta-Analysis

Jack T Seki, Reem Alsibai, Ruiqi Chen, Eshetu G. Atenafu, Hassan Sibai

Blood (2022) 140 (Supplement 1): 8898–8899.

https://doi.org/10.1182/blood-2022-167560

Published: 2022

Journal Articles

Ptcy-ATG-CSA Vs. ATG-MMF-CSA for Gvhd Prevention for 10/10 HLA Matched Unrelated Donor Allogeneic Hematopoietic Cell Transplantation

María Queralt Salas, Abel Santos Carreira, Eshetu G. Atenafu, Arjun D. Law, Wilson Lam, Ivan Pasic, Carol Chen, Dennis Dong Hwan Kim, Fotios V. Michelis, Armin Gerbitz, Jeffrey H. Lipton, Rajat Kumar, Jonas Mattsson, Auro Viswabandya

Blood (2022) 140 (Supplement 1): 4878–4879.

https://doi.org/10.1182/blood-2022-170142

Published: 2022

Journal Articles

Clinical Outcomes in De Novo Versus Secondary NPM1 -Mutated AML

Elliot C. Smith, Eshetu G. Atenafu, Aniket Bankar, Steven M. Chan, Marta B. Davidson, Vikas Gupta, Mark D. Minden, Guillaume Richard-Carpentier, Aaron D. Schimmer, Andre C. Schuh, Hassan Sibai, Karen Yee, Dawn Maze

Blood (2022) 140 (Supplement 1): 8952–8953.

https://doi.org/10.1182/blood-2022-166939

Published: 2022

Journal Articles

Risk Factor Analysis for Second Treatment-Free Remission Failure from the Canadian TKI Discontinuation (TRAD) Trial in CML Patients: Treatment-Free Remission Accomplished By Dasatinib

Maria Agustina Perusini, Eshetu G. Atenafu, Donna L. Forrest, Bence-Bruckler Isabelle, Lynn Savoie, Mary-Margaret Keating, Lambert Busque, Robert Delage, Anargyros Xenocostas, Elena Liew, Pierre Laneuville, Kristjan Paulson, Tracy L. Stockley, Jeffrey H. Lipton, Brian Leber, Dennis Dong Hwan Kim

Blood (2022) 140 (Supplement 1): 6778–6779.

https://doi.org/10.1182/blood-2022-167581

Published: 2022

Journal Articles

ATG-Ptcy-CSA for Gvhd Prevention in Peripheral Blood Haploidentical Hematopoietic Cell Transplantation for Adults with Hematological Malignancies

Maria Queralt Salas, Abel Santos Carreira, Eshetu G. Atenafu, Tommy Alfaro Moya, Arjun D. Law, Wilson Lam, Ivan Pasic, Carol Chen, Dennis Dong Hwan Kim, Fotios V. Michelis, Armin Gerbitz, Jeffrey H. Lipton, Rajat Kumar, Jonas Mattsson, Auro Viswabandya

Blood (2022) 140 (Supplement 1): 7625–7627.

https://doi.org/10.1182/blood-2022-170267

Published: 2022

Journal Articles

Myeloma Patients with Deletion of 17p: Impact of Tandem Transplant and Clone Size

Alfredo De La Torre, Eshetu G Atenafu, Adam C. Smith, Vishal Kukreti, Anca Prica, Sita Bhella, Donna E. Reece, Rodger E Tiedemann, Suzanne Trudel, Christine I. Chen

Blood (2021) 138 (Supplement 1): 460.

https://doi.org/10.1182/blood-2021-153011

Published: 2021

Journal Articles

Frailty Scale for Outcome Predictions in Hematopoietic Cell Transplanted Adults

Maria Queralt Salas, Eshetu G Atenafu, Eshrak Al-Shaibani, Ora Bascom, Leeann Wilson, Carol Chen, Ivan Pasic, Arjun Law, Wilson Lam, Dennis Dong Hwan Kim, Armin Gerbitz, Auro Viswabandya, Jeffrey H. Lipton, Fotios Michelis, Jonas Mattsson, Shabbir Alibhai, Rajat Kumar

Blood (2021) 138 (Supplement 1): 110.

https://doi.org/10.1182/blood-2021-153710

Published: 2021

Journal Articles

Efficacy of Daratumumab Containing Regimens Post Lenalidomide Maintenance in Transplant Eligible Patients: Real-World Experience from the Canadian Myeloma Research Group Database

Hira S Mian, MD, Christine Eisfeld, Christopher P. Venner, MD, Victor Jimenez-Zepeda, MD, Cyrus Khandanpour, MD, Arleigh McCurdy, MD BSc, Michael Sebag, MD PhD FRCPC, Kevin W Song, MD FRCPC, Richard Leblanc, MD FRCPC, Esther Masih-Khan, PhD, Eshetu G Atenafu, MSc, P.Stat, Darrell J White, MD, Julie Stakiw, MD, Anthony Reiman, MD, Martha L Louzada, MDMSc, Muhammad Aslam, MD, Rami Kotb, MD, Engin Gul, BS, MBA, Donna E. Reece, MD

Blood (2020) 136 (Supplement 1): 26–27.

https://doi.org/10.1182/blood-2020-133372

Published: 2020

Journal Articles

BCR-ABL1 Transcript Doubling Time after Imatinib Discontinuation for Treatment-Free Remission in Chronic Myeloid Leukemia in Chronic Phase: Predictor for Treatment-Free Remission Failure

Dennis Dong Hwan Kim, MD, Igor Nicolas Novitzky-Basso, MDPhDMRCP,FRCPath, Taehyung Kim, MSc, Eshetu G Atenafu, M.Sc., P.Stat, Donna L. Forrest, MD, Lynn Savoie, MD, Isabelle Bence-Bruckler, MD, Mary-Margaret Keating, MD FRCPC, Lambert Busque, MD, Robert Delage, MD, Anargyros Xenocostas, MD FRCPC, Elena Liew, MDBSc,FRCPC, Kristjan Paulson, MD, Tracy L. Stockley, PhD FCCMG, FACMG, Pierre Laneuville, MD FRCPC, Jeffrey H. Lipton, MD PhD, Suzanne Kamel-Reid, BA, MA, PhD FACMG, Brian Leber, MD

Blood (2020) 136 (Supplement 1): 40–41.

https://doi.org/10.1182/blood-2020-136162

Published: 2020

Journal Articles

CPX351 Has Short Remission Duration but Is an Effective Bridge to Allogeneic Transplant in High Risk AML: Results from Canadian Real-World Multi-Centre Study

Claire Andrews, Taylor Young, Eshetu G Atenafu, M.Sc., P.Stat, Sarit E Assouline, MD MSc, Joseph M Brandwein, MD, Steven M Chan, MD PhD, Signy Chow, MD FRCP(C), Dina Khalaf, BSc, MSc, MD, Vikas Gupta, MD FRCP, FRCPath, Dennis Dong Hwan Kim, MD, Dawn Maze, MDFRCPC,MSc, Mark D. Minden, Caroline J McNamara, MBBS, Tracy Murphy, MDFRCP,FRCPath, David Sanford, MD, Aaron D Schimmer, MD PhD, Andre C. Schuh, Karen W.L. Yee, MD, Hassan Sibai, MBBS

Blood (2020) 136 (Supplement 1): 6–7.

https://doi.org/10.1182/blood-2020-142990

Published: 2020

NARROW

Outcomes of Relapsed/Refractory Multiple Myeloma Patients Receiving Sequential Therapies after Exposure to T-Cell Redirected or BCMA-Targeted Novel Immunotherapies

Real-World Experience with CPX-351 for Secondary Acute Myeloid Leukemia: Comparison with FLAG-IDA in a Propensity Score Matching Analysis

Final Results of the Canadian Myeloma Research Group Trial of Cybord Induction, Double-Alkylator Conditioning with High-Dose Intravenous Busulfan + Melphalan, ASCT and Continuous Lenalidomide Maintenance for Patients with Newly Diagnosed Multiple Myeloma (CMRG-001)

Real World Outcomes in Adult Histiocytosis: 23-Year Canadian Single Center Analysis

Long Term Survivors (>15 years) of Multiple Myeloma: Patient Characteristics and Morbidity Burden

Correlation Amongst Scoring of Various Frailty Tools in Myeloma Patients Undergoing Autologous Stem Cell Transplantation

Comparison of Clinical Outcomes between Transplant and Non-Transplant Therapies in Myelofibrosis Following Failure of First-Line JAK-Inhibitor

Real-World Outcomes and Adverse Events of Elderly Patients with Ph-Negative Acute Lymphoblastic Leukemia Treated with a Pediatric-Inspired Protocol

Acute Lymphoblastic Leukemia in Patients 60 Years and Older Treated with Pediatric-Inspired Protocols, 20 Years of Follow-up

Do Adult Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Patients Require Allogeneic Transplant in First Remission (CR1)?

Which Asparaginase Formulation Retained Higher VTE Incidence Risk in Post Treatment Adult Acute Lymphoblastic Leukemia? a Meta-Analysis

Ptcy-ATG-CSA Vs. ATG-MMF-CSA for Gvhd Prevention for 10/10 HLA Matched Unrelated Donor Allogeneic Hematopoietic Cell Transplantation

Clinical Outcomes in De Novo Versus Secondary NPM1 -Mutated AML

Risk Factor Analysis for Second Treatment-Free Remission Failure from the Canadian TKI Discontinuation (TRAD) Trial in CML Patients: Treatment-Free Remission Accomplished By Dasatinib

ATG-Ptcy-CSA for Gvhd Prevention in Peripheral Blood Haploidentical Hematopoietic Cell Transplantation for Adults with Hematological Malignancies

Myeloma Patients with Deletion of 17p: Impact of Tandem Transplant and Clone Size

Frailty Scale for Outcome Predictions in Hematopoietic Cell Transplanted Adults

Efficacy of Daratumumab Containing Regimens Post Lenalidomide Maintenance in Transplant Eligible Patients: Real-World Experience from the Canadian Myeloma Research Group Database

BCR-ABL1 Transcript Doubling Time after Imatinib Discontinuation for Treatment-Free Remission in Chronic Myeloid Leukemia in Chronic Phase: Predictor for Treatment-Free Remission Failure

CPX351 Has Short Remission Duration but Is an Effective Bridge to Allogeneic Transplant in High Risk AML: Results from Canadian Real-World Multi-Centre Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only